- Home
- NXTC vs BOF Comparison
NXTC vs BOF Comparison
Compare NXTC & BOF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXTC
- BOF
- Stock Information
- Founded
- NXTC 2015
- BOF 2017
- Country
- NXTC United States
- BOF United States
- Employees
- NXTC N/A
- BOF N/A
- Industry
- NXTC Biotechnology: Pharmaceutical Preparations
- BOF Packaged Foods
- Sector
- NXTC Health Care
- BOF Consumer Staples
- Exchange
- NXTC Nasdaq
- BOF Nasdaq
- Market Cap
- NXTC 24.6M
- BOF 27.6M
- IPO Year
- NXTC 2019
- BOF 2023
- Fundamental
- Price
- NXTC $8.71
- BOF $3.27
- Analyst Decision
- NXTC Strong Buy
- BOF
- Analyst Count
- NXTC 3
- BOF 0
- Target Price
- NXTC $23.00
- BOF N/A
- AVG Volume (30 Days)
- NXTC 85.8K
- BOF 3.7M
- Earning Date
- NXTC 11-05-2025
- BOF 11-13-2025
- Dividend Yield
- NXTC N/A
- BOF N/A
- EPS Growth
- NXTC N/A
- BOF N/A
- EPS
- NXTC N/A
- BOF N/A
- Revenue
- NXTC N/A
- BOF $10,179,595.00
- Revenue This Year
- NXTC N/A
- BOF N/A
- Revenue Next Year
- NXTC N/A
- BOF N/A
- P/E Ratio
- NXTC N/A
- BOF N/A
- Revenue Growth
- NXTC N/A
- BOF 95.18
- 52 Week Low
- NXTC $2.69
- BOF $1.53
- 52 Week High
- NXTC $19.20
- BOF $3.37
- Technical
- Relative Strength Index (RSI)
- NXTC 46.50
- BOF 63.64
- Support Level
- NXTC $8.51
- BOF $2.79
- Resistance Level
- NXTC $10.56
- BOF $3.29
- Average True Range (ATR)
- NXTC 1.23
- BOF 0.33
- MACD
- NXTC -0.36
- BOF 0.02
- Stochastic Oscillator
- NXTC 1.93
- BOF 78.16
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.
About BOF BranchOut Food Inc.
Branchout Food inc is engaged in the development, marketing, sale, and distribution of plant-based, dehydrated fruit and vegetable snacks and powders. Its products are currently manufactured for the company by contract manufacturers based in South America and North America that produce dehydrated fruit and vegetable products for the company using a new proprietary dehydration technology that it licenses from a third party. The Company's customers are located throughout the United States. Its current primary products are BranchOut Snacks, BranchOut Powders, and BranchOut Industrial Ingredients.